# Dasatinib

Source: https://onco.cc/drugs/dasatinib/  
OnCo record `dasatinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Dasatinib is a second-generation BCR::ABL1 pill that, combined with the immunotherapy blinatumomab, can put Ph-positive ALL into deep remission with no chemotherapy at all.

## Summary

Approved in CML (2006) and Ph+ ALL (resistant, 2006; paediatric frontline with chemotherapy 2018). The GIMEMA D-ALBA trial (dasatinib induction then blinatumomab) achieved 18-month OS 95% and DFS 88% in adults, launching the chemotherapy-free paradigm; long-term follow-up shows ~75% DFS at 4 years, with IKZF1-plus and T315I as the relapse drivers. Generic since 2024.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-07
- Brand: Sprycel
- Modality: Small-molecule kinase inhibitor (BCR::ABL1, SRC)
- Mechanism: Dual SRC/ABL inhibitor binding active and inactive ABL1 conformations; inactive against T315I.
- Approvals: US 2006: CML and Ph+ ALL resistant or intolerant to imatinib; US 2018: Paediatric Ph+ ALL with chemotherapy
- Dosing: Oral; Ph+ ALL: 140 mg once daily (adult); paediatric weight-based; continue through consolidation and maintenance
- Toxicity (grade 3+): Myelosuppression 50%

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Dasatinib
- FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Dasatinib

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/), [Chronic myeloid leukaemia, accelerated and blast phase](https://onco.cc/cancers/cml-advanced-phase/), [Chronic myeloid leukaemia, chronic phase](https://onco.cc/cancers/cml-chronic-phase/), [Mixed-phenotype acute leukaemia](https://onco.cc/cancers/mixed-phenotype-acute-leukaemia/), [Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)](https://onco.cc/cancers/all-ph-like/), [Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)](https://onco.cc/cancers/all-paediatric-ph-positive/)
- technologies: [Senolytics after cancer treatment](https://onco.cc/technologies/rejuv-frontier-senolytics/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [ABL1](https://onco.cc/targets/abl1/), [BCR::ABL1 (Philadelphia chromosome)](https://onco.cc/targets/bcr-abl/), [DDR2 receptor kinase](https://onco.cc/targets/ddr2/), [EphA2 receptor](https://onco.cc/targets/epha2/), [FRK kinase](https://onco.cc/targets/frk/), [HCK kinase](https://onco.cc/targets/hck/), [LYN kinase](https://onco.cc/targets/lyn/), [PTK6 (BRK)](https://onco.cc/targets/ptk6/), [SRC family kinases](https://onco.cc/targets/src/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)
- terms: [BCR::ABL1 kinase domain mutations (T315I and others)](https://onco.cc/terms/abl1-kinase-domain-mutations/), [Molecular response (MMR, MR4, treatment-free remission)](https://onco.cc/terms/molecular-response/), [Ph-like (BCR::ABL1-like) acute lymphoblastic leukaemia](https://onco.cc/terms/ph-like-all/), [Ph-positive ALL](https://onco.cc/terms/ph-positive-all/), [Philadelphia chromosome (Ph+, BCR::ABL1)](https://onco.cc/terms/philadelphia-chromosome/), [Sokal and ELTS risk scores (chronic myeloid leukaemia)](https://onco.cc/terms/sokal-elts-scores/)
- trials: [A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP](https://onco.cc/trials/nct04971226/), [Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations](https://onco.cc/trials/nct02883049/), [D-ALBA (GIMEMA LAL2116)](https://onco.cc/trials/d-alba/), [DASISION](https://onco.cc/trials/dasision/), [READY](https://onco.cc/trials/ready-dasatinib/), [Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer](https://onco.cc/trials/nct05725200/), [TAPUR (Targeted Agent and Profiling Utilization Registry)](https://onco.cc/trials/tapur/)
- pairings: [BCR::ABL1 TKI + blinatumomab (chemotherapy-free Ph+ ALL)](https://onco.cc/pairings/tki-plus-blinatumomab-ph-all/)
- ideas: [Transplant-free Ph-positive ALL for MRD-negative adults](https://onco.cc/ideas/idea-transplant-free-ph-all/)
- pathways: [BCR::ABL1 (Philadelphia chromosome)](https://onco.cc/pathways/bcr-abl1-signalling/), [Chronic myeloid leukaemia (KEGG map)](https://onco.cc/pathways/cml-signalling/)
- people: [Charles L. Sawyers](https://onco.cc/people/charles-sawyers/)
- key papers: [Dasatinib versus imatinib with chemotherapy for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CCCG-ALL-2015)](https://onco.cc/key-papers/paper-dasatinib-vs-imatinib-ph-positive-all-shen-jama-oncol-2020/), [IRIS: imatinib versus interferon plus cytarabine as first treatment for chronic myeloid leukaemia](https://onco.cc/key-papers/paper-iris-imatinib-nejm-2003/)
- biomarkers: [BCR::ABL1 transcript (Philadelphia chromosome, quantitative PCR)](https://onco.cc/biomarkers/bcr-abl1-transcript/)

---
JSON: https://onco.cc/api/v1/entities/dasatinib.json